

International Collaborative Ovarian Neoplasm studies (1): A trial of adjuvant chemotherapy for early-stage ovarian cancer

Submission date 06/04/2000	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 06/04/2000	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 31/12/2021	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Sarah Wheeler

Contact details

MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
-
abc@email.com

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00002477

Protocol serial number

ICON1

Study information

Scientific Title

International Collaborative Ovarian Neoplasm studies 1 (ICON1): A trial of adjuvant chemotherapy for early-stage ovarian cancer

Acronym

ICON1

Study objectives

Currently it is not known whether adjuvant chemotherapy is of any benefit in ovarian cancer, and all previous trials have been too small to give reliable evidence. The prognosis for early disease is much better than for advanced disease, which is known to respond to platinum-based chemotherapy, and a similar response in early disease would prolong the lives of many thousands of women each year. However, any benefit must be weighed against the toxicity associated with the treatment employed, and hence reliable evidence regarding the size of any benefit to adjuvant treatment is needed.

The aim of the study was to compare immediate with deferred chemotherapy in patients with early stage epithelial ovarian cancer

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cancer

Interventions

Immediate chemotherapy or chemotherapy deferred until indicated

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Survival time; recurrence-free survival.

Key secondary outcome(s)

Not provided at time of registration

Completion date

21/01/2000

Eligibility

Key inclusion criteria

1. Chemotherapy not clearly indicated
2. No previous malignancy
3. No prior radiotherapy or chemotherapy
4. No contraindication to chemotherapy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Female

Total final enrolment

477

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1991

Date of final enrolment

21/01/2000

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
	Long-term follow-up				

Abstract results	20/06/2007	31/12/2021	No	No
Other publications	01/11/2001		Yes	No
Other publications	15/01/2003		Yes	No
Other publications	01/11/2003		Yes	No
Other publications	01/11/2003		Yes	No